Despite the association between Lp(a) elevations and coronary artery disease risk has emerged from both epidemiological and genetic studies [64–66], a pharmacological approach able to lower Lp(a) levels to the extent required to potentially achieve a CV benefit in patients with progressive ASCVD and high plasma Lp(a) is still missing (reviewed in [67]). Here, LPA is linked to coronary artery disorder.